The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)–Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results
Randomised controlled trialHumansWith rutin and hydroxytyrosol
This study tested palmitoylethanolamide together with rutin and hydroxytyrosol. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 19 patients with metabolic syndrome enrolled in a crossover design. 16 completed.
- Dose used in the study
- Two capsules a day, each with 360 mg of co-micronised palmitoylethanolamide-rutin and 15 mg of hydroxytyrosol
- Duration
- 8 weeks on each of supplement and placebo, with a 2-week washout
- What was measured
- Body weight and composition, markers of inflammation, blood pressure, glucose and lipids, quality of life and physical performance
What the authors reported
The authors reported small falls in body weight (86.4 to 85.3 kg), BMI and fat mass, and falls in CRP and ESR, during the supplement phase. The fall in IL-6 was not significant. There were no significant differences in waist measurements, blood pressure, fasting glucose, triglycerides or HDL cholesterol. No adverse events were reported.
Limits of this study
The authors call these preliminary results from about 30% of the planned sample. 16 patients completed. Many outcomes were measured. The funding statement was not visible on the page checked.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.